Press Releases

• June 9, 2023

  IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy

• April 4, 2023

  IgGenix Announces Patent Granted by USPTO Covering the Generation of Allergen-Specific Antibodies

• March 2, 2023

  IgGenix Demonstrated Potential for Single-Cell RNA-Sequencing to Address Shellfish Allergies at the 2023 AAAAI Annual Meeting

• February 6, 2023

  IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy

• August 19, 2022

  How Re-Engineering Antibodies Can Prevent Allergies (Labiotech.eu)

• July 1, 2022

  IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies

• April 26, 2022

  IgGenix Announces Move of Headquarters to Lilly Gateway Labs in South San Francisco

• February 23, 2022

  IgGenix Announces Presentation on Food Allergy Research at American Academy of Allergy, Asthma & Immunology Annual Meeting

• July 27, 2021

  IgGenix Announces $25M in Series A1 Funding

• June 24, 2021

  IgGenix Announces Jessica Grossman, M.D., as Chief Executive Officer

BACK